Showing 15 posts of 695 posts found.

EC approves Roche’s Evrysdi for babies under two months with SMA

August 30, 2023
Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …


Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis

June 16, 2023
Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis

Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …

Roche building

Roche’s Evrysdi drug for SMA shown to significantly increase survival

April 15, 2021
PTC Therapeutics, Roche, pharma, pharma news, spinal muscular atrophy

Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …

Novartis signs capacity and technology transfer agreement for Roche drug

April 15, 2021
Novartis, Roche, production

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …

Roche building

Roche’s SMA treatment Evrysdi approved by European Commission

March 30, 2021
Manufacturing and Production EMA, European Commission, PTC Therapeutics, Roche, sma, spinal muscular atrophy

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …

Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial

March 24, 2021
Research and Development COVID-19, Roche, covid-19 treatment

Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …

Roche's building

Roche’s Huntington’s disease treatment disappoints in Phase III trial

March 23, 2021
Manufacturing and Production Huntington's, Phase III trial, Roche, huntington's disease, tominersen

Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.


Roche lung cancer treatment reports promising results in Phase III

March 22, 2021
Sales and Marketing Roche, oncology

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …

Roche and PTC’s SMA treatment shows positive trial results

March 16, 2021
Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy

Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …

Roche building

Roche acquire GenMark in $1.8 billion deal

March 15, 2021
Sales and Marketing Diagnostics, GenMark, Roche

Pharmaceutical giant Roche have bought GenMark Diagnostics in a deal worth $1.8 billion, expanding their infectious disease testing for illnesses …


Roche voluntarily withdraws Tecentriq’s US bladder cancer indication

March 8, 2021
Sales and Marketing Cancer, Roche, bladder cancer, tecentriq

Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …

FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease

March 5, 2021
Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis

Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …


Roche’s influenza drug Xofluza gets EU approval

January 11, 2021
Sales and Marketing EC, Roche, influenza

The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 …

Roche secures emergency FDA approval for COVID-19 antibody test

December 3, 2020
Sales and Marketing COVID-19, FDA, Roche

The FDA has awarded Emergency Use Authorization to Roche’s COVID-19 test to allow users in the US to analyse the …

Latest content